Group 1 - YunKang Group (02325.HK) increased by 4.90% [1] - Tongyuan Kang Pharmaceutical-B (02410.HK) rose by 2.73% [1] - Yiming Anke-B (01541.HK) saw a rise of 2.63% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 浙江同源康醫藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02410 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 375,457,818 | RMB | | 1 RMB | | 375,457,818 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 375,457,818 | RMB | | 1 RMB | | 375,457,818 | | 2. ...

浙江同源康醫藥股份有限公司 第一條 為維護浙江同源康醫藥股份有限公司（以下簡稱「公司」）、股東、職 工和債權人的合法權益，規範公司的組織和行為，根據《中華人民共和國公司法》 （以下簡稱「《公司法》」）、《中華人民共和國證券法》（以下簡稱「《證券法》」）、《境 內企業境外發行證券和上市管理試行辦法》、《香港聯合交易所有限公司證券上市 規則》（以下簡稱「《香港上市規則》」）及其他相關法律、行政法規和規範性文件的 有關規定，並參照《上市公司章程指引》（以下簡稱「《上市公司章程指引》」），制定 本章程。 第二條 公司系依照《公司法》和其他有關規定成立的股份有限公司。 公司是由鄭州泰基鴻諾醫藥股份有限公司、貝沃特醫藥技術（上海）有限公司 依法發起設立的股份有限公司，在浙江省市場監督管理局註冊登記並取得《營業 執照》，統一社會信用代碼為91330500MA2B3D0G3Q。 章程 2025年10月 | 第一章 | 總則 | 3 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 5 | | 第三章 | 股份 | 5 | | 第一節 | 股份發行 | 5 | | 第二節 | 股份增減和回購 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 有關上述各項決議案的詳情，請參閱通函。 由於超過半數的票數贊成第(1)至(2)項普通決議案，且超過三分之二的票數贊成第 (3)至(4)項特別決議案，故上述第(1)至(2)項普通決議案及第(3)至(4)項特別決議 案已於臨時股東大會上獲股東以投票表決方式正式通過。本公司於香港的H股股 份過戶登記處香港中央證券登記有限公司獲委任為臨時股東大會投票表決的監票 員。 於臨時股東大會日期，已發行股份總數為380,065,818股股份，包括375,457,818股 H股及4,608,000股未上市股份。所有該等股份的持有人均有權出席臨時股東大會 並於會上投票贊成或反對或棄權所有於會上提呈的決議案。據董事所知、所悉及 所信及根據適用中國法律、法規及監管規定，概無股東須根據上市規則於臨時股 ...

Group 1 - The stock of Hong Kong-based company Tongyuan Kang Medical-B has risen nearly 7% in the morning session [1] - The current trading price is reported at 15.08 Hong Kong dollars [1] - The trading volume reached 73.088 million Hong Kong dollars [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant stock price increase, attributed to the announcement of early clinical research results for three CDK inhibitors to be presented at the 2025 ESMO annual meeting [1] Group 1: Stock Performance - The stock price of Tongyuan Kang Pharmaceutical-B rose nearly 7% in the morning session and is currently up 5.82%, trading at HKD 15.08 with a transaction volume of HKD 73.088 million [1] Group 2: Clinical Research Announcements - The company announced that three CDK inhibitors, TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), will have their early clinical research results presented as posters at the 2025 ESMO annual meeting scheduled for October 17-21 in Berlin, Germany [1] - Additionally, the company’s drug, Aidiotini Tablets (TY-9591), targeting brain metastases in non-small cell lung cancer, has garnered significant attention following its key Phase II clinical trial results presented at the World Lung Cancer Conference in September 2025 [1] Group 3: Regulatory Milestones - Aidiotini Tablets, a highly selective small molecule inhibitor developed for classic EGFR mutations, completed patient enrollment of 224 cases for conditional approval by November 2024 and is expected to submit a Pre-NDA application in April 2025, with a formal conditional NDA submission anticipated in Q4 2025 [1]

Core Viewpoint - The stock of Tongyuan Kang Pharmaceutical-B (02410) has seen a significant increase, rising nearly 7% before stabilizing at a 5.82% gain, trading at HKD 15.08 with a transaction volume of HKD 73.088 million [1] Group 1: Clinical Research Developments - The company announced early clinical research results for three cell cycle protein-dependent kinase inhibitors (CDKis): TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), which will be presented at the 2025 ESMO Annual Meeting in Berlin from October 17 to 21 [1] - Tongyuan Kang's drug, Aditinib (TY-9591), targeting non-small cell lung cancer brain metastases, has garnered significant attention following its key Phase II clinical trial results presented at the World Lung Cancer Conference in September 2025 [1] Group 2: Regulatory Milestones - The company completed the enrollment of 224 patients for the conditional approval of Aditinib in November 2024 and submitted a Pre-NDA application in April 2025, with plans to formally submit a conditional NDA application in Q4 2025 [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a stock price increase of over 3%, currently trading at 15.53 HKD with a transaction volume of 5.21 million HKD, following the announcement of early clinical research results for three CDK inhibitors [1] Group 1: Company Developments - On October 21, Tongyuan Kang Pharmaceutical-B announced that its board is pleased to present early clinical research results for three key drugs in the CDK inhibitor field: TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - The results were showcased in poster format at the European Society for Medical Oncology (ESMO) annual meeting, which is one of the most influential academic events in the oncology field [1] Group 2: Industry Context - The ESMO 2025 annual meeting is scheduled to take place from October 17-21, 2025, in Berlin, Germany, attracting top experts and scholars to discuss clinical challenges and share cutting-edge advancements [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has announced early clinical research results for three drugs in the cell cycle protein-dependent kinase inhibitor (CDKi) field, which were presented at the European Society for Medical Oncology (ESMO) annual meeting [1] Group 1: Company Performance - The stock price of Tongyuan Kang Pharmaceutical-B increased by over 3% at the beginning of trading and is currently up by 1.52%, trading at 15.40 HKD with a transaction volume of 18.24 million HKD [1] Group 2: Clinical Research and Events - The three drugs highlighted are TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), which are part of the company's strategic focus [1] - The ESMO 2025 annual meeting will take place from October 17-21, 2025, in Berlin, Germany, and is recognized as one of the most influential academic events in the oncology field, attracting top experts and scholars [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a stock price increase of over 3%, currently trading at 15.53 HKD with a transaction volume of 5.21 million HKD, following the announcement of early clinical research results for three CDK inhibitors at the ESMO 2025 conference [1] Company Summary - On October 21, Tongyuan Kang Pharmaceutical-B announced that its board is pleased to present early clinical research results for three key drugs in the cyclin-dependent kinase inhibitor (CDKi) field: TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - The results were showcased in poster format at the European Society for Medical Oncology (ESMO) 2025 conference, which is scheduled to take place from October 17-21, 2025, in Berlin, Germany [1] - ESMO is recognized as one of the most influential academic events in the oncology field, attracting top experts and providing a platform for discussing clinical challenges and sharing cutting-edge advancements [1]